Research output per year
Research output per year
Personal profile
Headline
ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
Biography
Fingerprint
Dive into the research topics where Joshua Brody is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Crombie, J. L., Graff, T., Falchi, L., Karimi, Y. H., Bannerji, R., Nastoupil, L., Thieblemont, C., Ursu, R., Bartlett, N., Nachar, V., Weiss, J., Osterson, J., Patel, K., Brody, J., Abramson, J. S., Lunning, M., Shah, N. N., Ayed, A., Kamdar, M. & Parsons, B. & 13 others, , 18 Apr 2024, In: Blood. 143, 16, p. 1565-1575 11 p.Research output: Contribution to journal › Comment/debate
Open Access25 Scopus citations -
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Degtyarev, E., Bolaños, N., Brody, J. D., Buchbinder, A., Buyse, M., Fuchs, M., Halabi, S., Hemmings, R., Masood, A., Newsome, S., Saxton, C., Warwick, L., Yateman, N. A. & Zuber, E., 2024, In: Future Oncology. 20, 22, p. 1601-1615 15 p.Research output: Contribution to journal › Comment/debate
Open Access -
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency
Aminov, S., Giricz, O., Melnekoff, D. T., Sica, R. A., Polishchuk, V., Papazoglu, C., Yates, B., Wang, H. W., Sahu, S., Wang, Y., Gordon-Mitchell, S., Leshchenko, V. V., Schinke, C., Pradhan, K., Aluri, S., Sohn, M., Barta, S. K., Agarwal, B., Goldfinger, M. & Mantzaris, I. & 7 others, , 15 Apr 2024, In: Journal of Clinical Investigation. 134, 8, e175199.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
Zinzani, P. L., Salles, G., Moskowitz, A. J., Santoro, A., Mehta, A., Barr, P. M., Mehta-Shah, N., Collins, G. P., Ansell, S. M., Brody, J. D., Domingo-Domenech, E., Johnson, N. A., Cunningham, D., Ferrari, S., Lisano, J., Krajewski, J., Wen, R., Akyol, A., Crowe, R. & Savage, K. J., 28 May 2024, In: Blood advances. 8, 10, p. 2400-2404 5 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
Tolcher, A. W., Brody, J. D., Rajakumaraswamy, N., Kuhne, M., Trowe, T., Dauki, A. M., Pai, S., Han, L., Lin, K. W., Petrarca, M. & Kummar, S., 15 Jul 2024, In: Clinical Cancer Research. 30, 14, p. 2954-2963 10 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations
Press/Media
-
-
Glofitamab Combination Therapy Shows Survival Benefit in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1/08/24
1 item of Media coverage
Press/Media
-
Preliminary Analysis Of Data Evaluating Investigational Epcoritamab (Duobody® Cd3xcd20) Combination Demonstrates 95% Overall Response Rate In Patients With Previously Untreated Follicular Lymphoma
2/06/24 → 3/06/24
15 items of Media coverage
Press/Media
-
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
2/06/24 → 3/06/24
3 items of Media coverage
Press/Media
-
READY-TO-GO T CELLS MAY BE RESPONSIBLE FOR IMMUNOTHERAPY SUCCESS IN CLASSICAL HODGKIN LYMPHOMA
4/04/24
1 item of Media coverage
Press/Media